Perimenopause Exact Monitoring Schedule: What Tests, When, and Why

What Is the STRAW+10 Staging System and Why Does It Drive the Monitoring Schedule?

STRAW+10 (Stages of Reproductive Aging Workshop, updated 2012) is the international reference framework for classifying the menopause transition. Every major monitoring decision anchors to the stage a woman occupies, because labs, symptoms, and treatment needs differ substantially between early perimenopause (Stage -2) and late perimenopause (Stage -1).

Defining the Stages

Stage -2 (early menopausal transition) is marked by cycle length variation of 7 or more days in at least two of the last 10 cycles [1]. Cycles remain present but erratic. Vasomotor symptoms may appear.

Stage -1 (late menopausal transition) requires at least two skipped cycles and an amenorrhea interval of 60 or more days. FSH frequently exceeds 25 IU/L on cycle days 2 to 5, and estradiol often falls below 50 pg/mL [1]. Hot flashes, sleep disruption, and mood changes peak during this stage.

Stage +1a (early postmenopause) begins the day after 12 consecutive months of amenorrhea. This article addresses stages -2 and -1, but the monitoring schedule described here sets up the postmenopause protocol seamlessly.

Why FSH Alone Is Not a Diagnostic Test

FSH fluctuates widely during perimenopause. A single elevated FSH does not confirm the diagnosis and a single normal FSH does not rule it out [2]. The Endocrine Society's 2015 clinical practice guideline on menopause states: "The diagnosis of perimenopause is clinical and based on menstrual cycle changes; serum FSH should not be used as the sole criterion" [3]. FSH testing is most useful for ruling out premature ovarian insufficiency in women under age 40, or for counseling on contraceptive need.

Baseline Evaluation at Entry Into Perimenopause

When a patient first meets STRAW+10 Stage -2 criteria, a structured baseline assessment establishes the individual risk profile that drives all future monitoring intervals.

Symptom Documentation

Use the Menopause Rating Scale (MRS) or Greene Climacteric Scale at baseline to quantify vasomotor, psychological, and urogenital symptom burden. A baseline score provides an objective comparator at 6-month follow-ups. Ask specifically about sleep quality, because poor sleep independently raises cardiovascular risk and is one of the three most-reported symptoms in perimenopause cohort data [4].

Baseline Laboratory Panel

Order the following at the first perimenopause visit:

• FSH and estradiol on cycle days 2-5 (or any day if cycles are absent for more than 60 days)
• TSH, thyroid dysfunction mimics hot flashes, mood changes, and cycle irregularity; prevalence of subclinical hypothyroidism in midlife women is approximately 8-10% [5]
• Fasting glucose and HbA1c, the Women's Health Initiative Observational Study (N=93,676) showed a 17% higher risk of incident type 2 diabetes around the menopause transition [6]
• Fasting lipid panel, LDL rises approximately 10-15 mg/dL in the two years surrounding the final menstrual period [7]
• CBC, heavy perimenopausal bleeding causes iron-deficiency anemia in roughly 25% of women with cycle changes
• Blood pressure, measured twice, two minutes apart; hypertension prevalence increases from roughly 30% in early perimenopause to 52% by the early postmenopause years [8]
• BMI and waist circumference, central adiposity accelerates during the transition even without weight gain on the scale

Pelvic and Breast Screening

A cervical cytology (Pap) schedule should comply with USPSTF 2018 guidelines: co-testing every 5 years from age 30 to 65, or cytology alone every 3 years [9]. Mammography should begin by age 40 and repeat every 1 to 2 years per the USPSTF 2024 update [10].

Bone Density Monitoring During Perimenopause

Bone loss accelerates during the menopause transition. The late perimenopause and early postmenopause period accounts for roughly 5% of total bone mass loss per year at the spine [11].

When to Order the First DXA Scan

The National Osteoporosis Foundation recommends a baseline dual-energy X-ray absorptiometry (DXA) scan in all postmenopausal women and in perimenopausal women with one or more clinical risk factors, including current smoking, low body weight (BMI <20), glucocorticoid use exceeding 3 months, or a personal history of fragility fracture [11]. Without risk factors, the first scan can wait until menopause confirmation (12 months of amenorrhea) or age 50, whichever comes first.

DXA Repeat Intervals

If the baseline T-score is above -1.5, repeat DXA every 3 to 5 years. If the T-score falls between -1.5 and -2.4 (osteopenia range), repeat at 1 to 2 years. A T-score at or below -2.5 meets criteria for osteoporosis and triggers fracture-risk assessment using FRAX, plus a conversation about bisphosphonates or hormone therapy [11].

Vitamin D and Calcium Checks

Order serum 25-hydroxyvitamin D at baseline. The Endocrine Society defines sufficiency as 30 ng/mL or above and recommends 1,500-2,000 IU/day of vitamin D3 for adults at risk of deficiency [12]. Dietary calcium intake should be reviewed; the target is 1,200 mg/day from food plus supplements combined for women over 50.

Cardiovascular Monitoring During the Menopause Transition

Cardiovascular disease risk rises substantially after the final menstrual period. The SWAN (Study of Women's Health Across the Nation) cohort showed that subclinical atherosclerosis, measured by carotid intima-media thickness, increases at a faster rate during the late perimenopause stage than in premenopausal controls, independent of traditional risk factors [7].

Annual Cardiovascular Checks

Repeat the following every 12 months throughout the perimenopause transition:

• Fasting lipid panel (LDL, HDL, triglycerides, non-HDL cholesterol)
• Fasting glucose or HbA1c
• Blood pressure
• BMI and waist circumference
• Smoking status documentation

The American Heart Association's 2020 statement on menopause and cardiovascular disease notes: "Clinicians should incorporate menopausal status and history into the cardiovascular risk assessment of all female patients" [8].

10-Year ASCVD Risk Calculation

Calculate the pooled cohort equation (PCE) score at baseline and update it annually once a woman is in late perimenopause or postmenopause. A score above 7.5% triggers a shared decision-making conversation about statin therapy per ACC/AHA 2019 guidelines.

Hormone Therapy Monitoring Schedule

Starting hormone therapy in perimenopause requires a structured reassessment calendar. The goal is to use the lowest effective dose for the shortest duration that controls symptoms while maintaining an acceptable safety profile.

Initiation Checklist

Before starting any systemic estrogen, confirm:

1. No undiagnosed vaginal bleeding
2. No active or recent breast cancer (within 10 years for most regimens)
3. No active venous thromboembolism or high-risk thrombophilia
4. No current liver disease with abnormal enzymes

Transdermal estrogen (patches, gels, sprays) avoids first-pass hepatic metabolism and carries a lower venous thromboembolism risk than oral formulations. A 2019 meta-analysis of 58 observational studies (N over 3 million woman-years) found that oral estrogen doubled VTE risk (OR 2.0, 95% CI 1.6-2.5), while transdermal estrogen showed no significant elevation (OR 0.96, 95% CI 0.7-1.3) [13].

Follow-Up at 6 Weeks Post-Initiation

The first follow-up visit after starting HRT focuses on symptom response and tolerability:

• Re-administer the MRS or Greene scale to compare with baseline
• Review any breakthrough or unscheduled bleeding
• Check blood pressure, particularly with oral regimens containing progestin
• Assess for breast tenderness, bloating, and mood changes; these often resolve by week 8-12

Follow-Up at 3 Months

• Repeat FSH and estradiol only if symptoms remain uncontrolled, to guide dose adjustment
• Review uterine status: any woman with an intact uterus receiving systemic estrogen must have adequate progestogen coverage to prevent endometrial hyperplasia [3]
• Confirm mammogram is current

Annual HRT Review

The North American Menopause Society (NAMS) 2022 position statement recommends annual HRT review addressing four domains: symptom control, cardiovascular risk, breast cancer risk, and bone protection [14]. The review should include:

• Updated symptom scores (MRS or comparable tool)
• Blood pressure and lipid panel
• Mammogram confirmation
• Discussion of duration: the "timing hypothesis" from the Women's Health Initiative Memory Study reanalysis suggests cardiovascular benefit is most likely when hormone therapy begins within 10 years of the final menstrual period or before age 60 [14]

When to Order an Endometrial Biopsy

Unscheduled uterine bleeding requires investigation. Order a transvaginal ultrasound as the first step; an endometrial stripe below 4 mm in a postmenopausal woman has a negative predictive value of approximately 99% for endometrial cancer [15]. If bleeding persists beyond 3 months on HRT, or if the endometrial stripe exceeds 4 mm, proceed to office endometrial biopsy regardless of HRT formulation.

Non-Hormonal Treatment Monitoring

Women who cannot or choose not to use HRT still require structured follow-up. Non-hormonal options with the best evidence include SSRIs/SNRIs (particularly paroxetine 7.5 mg, the only FDA-approved non-hormonal treatment for vasomotor symptoms), gabapentin, and fezolinetant.

Fezolinetant Monitoring

Fezolinetant (Veozah, 45 mg daily) received FDA approval in May 2023 as the first neurokinin 3 receptor antagonist for moderate-to-severe vasomotor symptoms [16]. The SKYLIGHT 1 trial (N=501) showed a 59% reduction in moderate-to-severe hot flash frequency at week 12 versus 40% for placebo (P<0.001) [16].

Liver function monitoring is required: obtain baseline ALT/AST before starting, at 3 months, and at 6 months. Fezolinetant is contraindicated if ALT or AST exceeds 3 times the upper limit of normal at baseline.

Paroxetine 7.5 mg Monitoring

Re-evaluate symptom burden at 4 to 6 weeks. Screen for SSRI discontinuation symptoms before stopping; taper over 2 weeks minimum. Annual review of mood, sleep, and sexual function is appropriate given the drug's potential to reduce libido.

Mental Health and Cognitive Monitoring

Depression risk at least doubles during the perimenopause transition compared with the premenopausal baseline. The Harvard Study of Moods and Cycles (N=460) found that women with a history of depression had a 4-fold increased risk of a recurrent major depressive episode during perimenopause [4].

Routine Screening Tools

Administer the PHQ-9 at baseline and at every annual review. A score of 10 or above warrants clinical evaluation for major depressive disorder. Screen for anxiety using the GAD-7, particularly in women reporting significant sleep disruption.

Cognitive complaints ("brain fog," word-finding difficulty) are reported by up to 60% of perimenopausal women in community samples [4]. A brief objective test such as the Montreal Cognitive Assessment (MoCA) at baseline provides a comparator if complaints escalate, though current evidence does not support routine formal neuropsychological testing in asymptomatic women.

A Condensed Perimenopause Monitoring Timeline

The following schedule integrates STRAW+10 staging with NAMS, Endocrine Society, USPSTF, and AHA recommendations into a single clinical reference:

At Perimenopause Diagnosis (STRAW -2 Entry) FSH, estradiol (cycle days 2-5), TSH, CBC, fasting glucose, HbA1c, fasting lipid panel, blood pressure (x2), BMI plus waist circumference, cervical cytology per USPSTF schedule, mammogram per USPSTF 2024, MRS or Greene scale symptom score, PHQ-9, GAD-7, 25-OH vitamin D, DXA if risk factors present.

6 Weeks After Starting Any New HRT or Non-Hormonal Rx Symptom score re-administration, blood pressure, breakthrough bleeding assessment, medication tolerance review.

3 Months After HRT Initiation FSH and estradiol if symptoms uncontrolled, endometrial status review if any unscheduled bleeding, mammogram confirmation.

Every 6 Months in Year 1 of Any HRT Regimen Symptom scores, blood pressure, medication tolerance, uterine bleeding review.

Annually Throughout Perimenopause (All Women) Fasting lipid panel, fasting glucose or HbA1c, blood pressure, BMI plus waist circumference, TSH, CBC, PHQ-9, GAD-7, smoking status, mammogram per schedule, ASCVD risk score update, HRT benefit-risk review if applicable, 25-OH vitamin D.

Every 1-2 Years (Risk-Dependent) DXA (if T-score -1.5 to -2.4 or new risk factors), endometrial biopsy (if persistent unscheduled bleeding or stripe above 4 mm), colonoscopy per standard screening guidelines.

Every 3-5 Years DXA repeat (if baseline T-score above -1.5 and no new risk factors), FRAX update.

Special Populations and Modified Schedules

Premature Ovarian Insufficiency (Under Age 40)

Women with POI require immediate FSH confirmation (two FSH values above 40 IU/L, 4 to 6 weeks apart), karyotype, and autoimmune antibody panel (anti-adrenal, anti-thyroid). Bone density should be measured at diagnosis, not deferred. Hormone therapy is typically recommended until the natural age of menopause (approximately age 51) to protect bone, cardiovascular, and cognitive health [3].

Perimenopausal Women on Oral Contraceptives

Low-dose combined oral contraceptives (COCs) mask cycle changes and FSH fluctuations, making STRAW staging impossible during active pill use. To assess menopausal status, check FSH on cycle day 1-3 of the pill-free interval after age 50; an FSH above 30 IU/L on two occasions 6 weeks apart suggests the underlying ovarian reserve is menopausal [3]. Continue COCs until age 50 to 55 if the woman desires contraception; then reassess for transition to low-dose HRT.

Women With Breast Cancer History

Systemic estrogen is generally avoided in women with hormone receptor-positive breast cancer. Non-hormonal vasomotor treatment options, symptom monitoring every 3 to 6 months, and vaginal moisturizers for genitourinary syndrome are the standard approach. Annual DXA is appropriate given accelerated bone loss from aromatase inhibitor therapy.

Contraception During Perimenopause

Ovulation remains possible throughout perimenopause. Unintended pregnancy rates in women aged 40 to 44 are approximately 40 per 1,000 women-years, and in women aged 45 to 49 approximately 10 per 1,000 women-years, lower than in younger women but not negligible [17]. Contraception should be continued until 12 consecutive months of amenorrhea (the clinical definition of menopause) have been confirmed in women over age 50, or 24 months in women under 50.

The levonorgestrel-releasing intrauterine system (LNG-IUS, 52 mg) serves dual purposes in perimenopause: it provides contraception and acts as the progestogen component of an HRT regimen when combined with systemic estrogen.